Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$4.54

From 52W high−76.96%

Volume734729.00

Market cap$86.26M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$4.54

From 52W high

−76.96%

Volume

734729.00

Market cap

$86.26M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.3x

P/E (TTM)

—

RSI (14)

21.4

MomentumView details →

1D Return

−1.33%

YTD Return

−45.09%

SummaryUpdated Jun 1, 2026

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a biopharmaceutical company founded in 2009 and headquartered in Norwood, Massachusetts. The company went public in October 2014 and focuses on developing innovative immune modulators for treating immuno-oncology and fibrosis diseases. Corbus operates as a clinical-stage biotechnology company, meaning it is primarily engaged in research and development activities rather than commercial product sales, with multiple drug candidates in various stages of clinical trials.

Ask drillr about Corbus Pharmaceuticals Holdings, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.8x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−99.67%

ROA (TTM)

−80.25%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−36.13%

FCF YoY

−49.71%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−60.33%

EBITDA YoY

−72.90%

MomentumView details →

1D Return

−1.33%

YTD Return

−45.09%

1Y Return

−75.55%

RSI (14)

21.4

vs 50D SMA

−45.53%

vs 200D SMA

−49.19%

Capital & dividendView details →

Debt/Equity

0.04x

Current Ratio

5.71x

Quick Ratio

5.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.81

EPS Surprise

−43.65%

Beats (12Q)

7/12

Next Q EPS Est

−$1.32

Avg Surprise (4Q)

−7.30%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−101.90M

Op. CF (TTM)

−86.67M

Next earningsNov 11, 2026 →

Latest newsMore news →

Corbus Pharmaceuticals announced that the first patient has been dosed in its TEMPO-1 registrational study of CRB-701 in second-line and beyond oropharyngeal squamous cell carcinoma.21d ago

Corbus Pharmaceuticals Holdings reported topline results from its CANYON-1 Phase 1b trial evaluating CRB-913 as an obesity treatment, with the drug avoiding depressive effects.35d ago

Similar companies

Rallybio CorporationRLYB Milestone Pharmaceuticals Inc.MIST Tenaya Therapeutics, Inc.TNYA Lixte Biotechnology Holdings, Inc.LIXT Atara Biotherapeutics, Inc.ATRA Neumora Therapeutics, Inc. Common StockNMRA Find similar companies →

Latest newsMore news →

Corbus Pharmaceuticals announced that the first patient has been dosed in its TEMPO-1 registrational study of CRB-701 in second-line and beyond oropharyngeal squamous cell carcinoma.21d ago Corbus Pharmaceuticals Holdings reported topline results from its CANYON-1 Phase 1b trial evaluating CRB-913 as an obesity treatment, with the drug avoiding depressive effects.35d ago